EU Nephrologists Foresee Travere/CSL Vifor's FILSPARITM
Data from Spherix Global Insights' second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan),...
Source: globenewswire.com
Chart Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Chart Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Chart Dynamix Today - Breaking & Trending Today
Charting New Paths: Non-TNF's Evolving in Rheumatoid
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market...
Source: globenewswire.com
Rate of Switching from Regeneron's Eylea to Genentech's Vabysmo Doubled Over Past Year for ... | Region
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun
Source: eagletribune.com
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have
Source: benzinga.com
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning ...
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management
Source: bakersfield.com